<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851535</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK017</org_study_id>
    <nct_id>NCT04851535</nct_id>
  </id_info>
  <brief_title>Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refratory of Ruxolitinib Treatment.</brief_title>
  <official_title>A Phase II Study To Evaluate The Efficacy And Safety of Jaktinib Hydrochloride Tablets In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate&#xD;
      the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or&#xD;
      refractory of ruxolitinib treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will receive a minimum of 6 treatment cycles or 24 weeks (a 28-day treatment&#xD;
      cycle is defined as one treatment cycle).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spleen Volume Response rate (SVRR) at Week 24</measure>
    <time_frame>at Week 24</time_frame>
    <description>The proportion of subjects with spleen volume reduction from baseline ≥ 35% measured by MRI or CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Objective Response Rate (complete remission (CR) + partial remission (PR))</measure>
    <time_frame>Baseline, up to Year 2</time_frame>
    <description>International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen Response</measure>
    <time_frame>up to Year 2</time_frame>
    <description>Best response rate: the proportion of subjects with at least one spleen volume reduction ≥ 35% against the baseline; Time to response: the length of time from the date of first dose to the date on which the first spleen volume reduction ≥ 35% against the baseline; Duration of maintenance of at least 35% Reduction in Spleen Volume (DoMSR): the length of time from the date of the first spleen volume reduction ≥ 35% against the baseline to the date of the spleen volume reduction is less than 35% against the baseline due to spleen volume increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia Response</measure>
    <time_frame>up to Year 2</time_frame>
    <description>Proportion of transfusion dependent patients（Transfusion dependent patients：received RBC transfusion ≥ 12 U within 12 weeks before receiving the investigational drug） at baseline turned to non-transfusion dependent patients (non-transfusion dependent patients: no transfusion for at least 12 consecutive weeks and Hgb ≥ 85 g/L); Proportion of hemoglobin (Hgb) elevation ≥ 20 g/L in non-transfusion dependent patients (Hgb ≤ 100 g/L) at baseline; Decline in red blood cell (RBC) transfusion dependence: Number of RBC transfusions decreases by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of MF-related symptoms</measure>
    <time_frame>Baseline, up to Year 2</time_frame>
    <description>Proportion of patients with Myeloproliferative neoplasm symptom assessment form (MPN-SAF) TSS decreasing from basline by ≥ 50%; The change in MPN-SAF TSS from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the date of first dose to the earliest date of either increase in spleen volume ≥ 25% from on-study nadir or death, up to Year 2</time_frame>
    <description>The length of time from the date of first dose to the date of any of the following events: 1) ≥ 25% increase in spleen volume over nadir since the treatment; 2) death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival (LFS)</measure>
    <time_frame>From the date of first dose to the earliest date of either leukemia or death, up to Year 2</time_frame>
    <description>The length of time from the date of first dose to the date of any of the following events: 1) the first bone marrow blast count ≥ 20%; 2) the first peripheral blast count ≥ 20% ; 3) death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of first dose to the date of death, up to Year 2</time_frame>
    <description>The length of time from the date of first dose to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Hydrochloride Tablets</intervention_name>
    <description>Jaktinib 100mg Bid</description>
    <arm_group_label>Jaktinib 100mg Bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects voluntarily sign the informed consent form (ICF);&#xD;
&#xD;
          -  Age ≥ 18 years, either male or female;&#xD;
&#xD;
          -  Subjects diagnosed with a PMF according to World Health Organiztion (WHO) criteria&#xD;
             (2016 Edition), or patients diagnosed with a Post-PV-MF or Post-EF-MF according to&#xD;
             International Working Group for Myeloproliferative Neoplasms Research and Treatment&#xD;
             (2007 IWG-MRT) criteria;&#xD;
&#xD;
          -  Subjects with intermediate-2 or high-risk myelofibrosis, or Intermediate-1&#xD;
             myelofibrosis with symptoms according to the Dynamic International Prognostic System&#xD;
             (DIPSS) scoring system;&#xD;
&#xD;
          -  Subjects are relapsed/refractory to Ruxolitinib:&#xD;
&#xD;
               1. Relapsed defined as Ruxolitinib treatment for ≥ 3 months, following an initial&#xD;
                  response, regrowth to &lt; 10% spleen volume reduction (SVR) by MRI or &lt; 30%&#xD;
                  decrease in spleen size by palpation from baseline;&#xD;
&#xD;
               2. Refractory defeined as Ruxolitinib treatment for ≥ 3 months observed inadequate&#xD;
                  efficacy response: &lt; 10%volume SVR by MRI or &lt; 30% decrease in spleen size by&#xD;
                  palpation from baseline.&#xD;
&#xD;
          -  Subject has a measurable splenomegaly: spleen volume of ≥ 450 cm3 by MRI/CT and ≥ 5 cm&#xD;
             below left costal margin by palpation spleen measuring;&#xD;
&#xD;
          -  Expected life expectancy is greater than 24 weeks;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance Score 0-2;&#xD;
&#xD;
          -  Laboratory examination within 7 days before the randomization, fulfilling the&#xD;
             following criteria:&#xD;
&#xD;
        Neutrophil count ≥ 0.75 x 109/L, platelet count ≥ 75 x 109/L; Peripheral blood blasts ≤&#xD;
        10%; ALT and AST≤ 3 ULN, DBIL ≤ 2.0 ULN; Serum creatinine ≤ 2.0 ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have been previously exposed to Janus kinase (JAK) inhibitors other than&#xD;
             Ruxolitinib for a total of&gt; 2 weeks;&#xD;
&#xD;
          -  Subjects who have taken Ruxolitinib or other JAK inhibitor within 1 week prior to&#xD;
             screening;&#xD;
&#xD;
          -  Subjects with any significant clinical and laboratory abnormalities which may affect&#xD;
             the safety evaluation, such as uncontrolled diabetes, uncontrolled hypertension after&#xD;
             taking two or more hypotensive drugs or peripheral neuropathy;&#xD;
&#xD;
          -  Subjects with congestive heart failure (NCI-CTCAE V5.0) Class II or above,&#xD;
             uncontrolled or unstable angina or myocardial infarction, cerebrovascular accident, or&#xD;
             pulmonary embolism within 6 months prior to screening;&#xD;
&#xD;
          -  Subjects who have a history of chronic or recurrent respiratory diseases, such as:&#xD;
             chronic obstructive pulmonary disease, recurrent lung infections, etc., or have a&#xD;
             history of lung infections within 3 months before screening, or currently have upper&#xD;
             respiratory tract infections that have not recovered;&#xD;
&#xD;
          -  Subjects who have not fully recovered from surgical operation within 4 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Subjects suffering from arrhythmia and requiring treatment, or QTcB &gt; 480ms at&#xD;
             screening;&#xD;
&#xD;
          -  Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal&#xD;
             infections requiring treatment at screening;&#xD;
&#xD;
          -  Subjects who had undergone splenectomy, or received radiotherapy to the spleen within&#xD;
             6 months before screening;&#xD;
&#xD;
          -  Subjects with known human immunodeficiency virus (HIV), known active infectious&#xD;
             Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC);&#xD;
&#xD;
          -  Female subjects who are pregnant, currently breastfeeding, planning to become&#xD;
             pregnant;&#xD;
&#xD;
          -  Subjects who had experienced malignant tumors (except for adequately treated local&#xD;
             basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that&#xD;
             have been cured) or in combination with other serious diseases within the past 5&#xD;
             years;&#xD;
&#xD;
          -  Subjects who have participated in another clinical trial of a new drug or medical&#xD;
             instrument within 1 month before screening.&#xD;
&#xD;
          -  Subjects who have any other conditions that are not specified in the protocol but the&#xD;
             investigator believes that they are not suitable for inclusion in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, PhD</last_name>
    <phone>+8657187236896</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

